Accueil   Agenda - News   Toutes les news EDAP Announces First Patients Treated in Phase 2 Study of Focal One for the Treatment of Deep Invasive Endometriosis

EDAP Announces First Patients Treated in Phase 2 Study of Focal One for the Treatment of Deep Invasive Endometriosis

 

LYON, France, September 3, 2020 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced that the first two patients have been treated in the company’s Phase 2 clinical trial assessing Focal One® High Intensity Focused Ultrasound (HIFU) as a potential treatment for deep rectal endometriosis. A total of 38 women will be enrolled in the study and treated at five major hospitals and assessed over a six-month follow-up period. Follow-up of these patients will evaluate the safety and efficacy of HIFU for this pathology. Additional patients continue to be enrolled.

 

Lire le communiqué de presse